Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock financial statements, including revenue, expenses, profit, and loss
The total revenue of FBIOP for the last quarter is 13.03 M USD, and it's 34.67% lower compared to the previous quarter. The net income of Q1 24 is -15.42 M USD.